AI-generated analysis. Always verify with the original filing.
RenovoRx, Inc. entered into a Securities Purchase Agreement on March 17, 2026, for a private placement offering to 15 investors, closing on March 20, 2026, issuing 8,438,790 shares of common stock, pre-funded warrants for 2,200,000 shares, and milestone warrants for 5,319,392 shares for gross proceeds of approximately $10 million before fees. The offering relies on Section 4(a)(2) and Rule 506 of Regulation D exemptions from registration.
Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. On March 17, 2026, RenovoRx, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agre
. Unregistered Sales of Equity Securities. To the extent required by Item 3.02 of Form 8-K, the information contained in Item 1.01 of this Current Report on For
. Other Information. On March 18, 2026, the Company issued a press release regarding the pricing of the Offering. Such press release is filed as Exhibit 99.1 to
. Financial Statements and Exhibits. (d) Exhibits. No. Exhibit 4.1 Form of Pre-Funded Warrant Issued to Investors in the March 2026 Private Placement. 4.2 Form
Material Agreement